Endocrine Abstracts

Purpose: We aim at prospectively comparing the detection rate of GLP1-R PET/CT vs GLP1-R SPECT/CT vs standardized contrast enhanced 3T-MRI in patients with suspected insulinoma.Methods: 40 patients with neuroglycopenic symptoms due to endogenous hyperinsulinemic hypoglycemia were enrolled.3T-MRI was performed. Afterwards patients received SPECT/CT after injection of 111In-DOTA-exendin-4 and PET/CT after injection of <sup...

Purpose: The aim of our study is to compare the detection rate of GLP-1R PET/CT and GLP-1R SPECT/CT in patients with a biochemically proven endogenous hyperinsulinemic hypoglycemia. Preliminary results of an ongoing study are reported.Methods: Thirty-three patients (25 females, 8 males, age range 18–80 years, mean 49 years) with neuroglycopenic symptoms due to endogenous hyperinsulinemic hypoglycemia were enrolled (ClinicalTrials.gov, NCT02127541).<...

Introduction: Surgery is often the only treatment option that can effectively treat patients with insulinoma in MEN-1. However, the surgical intervention should be limited as surgery can not cure patients with MEN-1. It is, therefore, mandatory to correctly localize insulin secreting tumors from other neuroendocrine tumors.Materials and Methods: In this report we include 6 patients with proven endogenous hyperinsulinemic hypoglycemia and neuroglycopenia ...

Purpose: We aim at prospectively comparing the detection rate of glucagon-like peptide 1 receptor (GLP1R) PET/CT vs GLP1R SPECT/CT vs standardised contrast enhanced 3T MRI in patients with endogenous hyperinsulinaemic hypoglycaemia.Methods: 14 patients with neuroglycopenic symptoms due to endogenous hyperinsulinaemic hypoglycaemia were already enrolled (mean age 56 years, ten females and four males). A standardized contrast enhanced 3T MRI was performed....

Introduction: The management of patients with neuroendocrine neoplasms (NEN) has been revolutionised since the introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SSTR). Accurate assessment of SSTR status of primary focus/metastases is crucial to determine the choice of the treatment method. Recently it has been shown that novel molecular probes, SST2-antagonists, recognize more binding sites in comparison to the wide...